Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Assets (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Other Non-Current Assets for 15 consecutive years, with $59.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 14.42% year-over-year to $59.5 million, compared with a TTM value of $59.5 million through Dec 2025, up 14.42%, and an annual FY2025 reading of $59.5 million, up 14.42% over the prior year.
  • Other Non-Current Assets was $59.5 million for Q4 2025 at Neurocrine Biosciences, up from $20.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $61.6 million in Q3 2024 and bottomed at $3.2 million in Q1 2021.
  • Average Other Non-Current Assets over 4 years is $30.5 million, with a median of $28.8 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets plummeted 99.23% in 2021, then skyrocketed 552.56% in 2024.
  • Year by year, Other Non-Current Assets stood at $3.2 million in 2021, then surged by 1450.0% to $49.6 million in 2023, then increased by 4.84% to $52.0 million in 2024, then grew by 14.42% to $59.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for NBIX at $59.5 million in Q4 2025, $20.3 million in Q3 2025, and $21.6 million in Q2 2025.